Peregrine Pharmaceuticals
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Peregrine Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count).
Peregrine Pharmaceuticals: 12 sponsored US clinical trials, none currently recruiting.
Peregrine Pharmaceuticals sponsors 12 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 11 completed. 1 of these trials are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Tumors, with 1 trials.
Top-decile sponsor footprint
Peregrine Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
11 of 12 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
12 total, page 1 of 1
Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer
NCT01999673
Open-label, Single Arm, Tumor Imaging and Dosimetry Study of I-124 PGN650 in Advanced Solid Tumors
NCT01632696
Trial of Gemcitabine With or Without Bavituximab in Patients With Previously Untreated Stage IV Pancreatic Cancer
NCT01272791
Study of Bavituximab Plus Docetaxel in Patients With Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer
NCT01138163
Study of Paclitaxel/Carboplatin With or Without Bavituximab in Previously Untreated Non Small-Cell Lung Cancer
NCT01160601
Dose Confirmation Study of Cotara for the Treatment of Glioblastoma Multiforme at First Relapse
NCT00677716
Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus
NCT00503347
Safety & Radiation Distribution Study of Cotara® in Patients With Recurrent Glioblastoma Multiforme
NCT00509301
Repeat-Dose Study of Bavituximab in Patients With Chronic Hepatitis C
NCT00343525
Study of Bavituximab in Patients With Chronic Hepatitis C Virus Infection
NCT00128271
Study of Bavituximab in Patients With Advanced Solid Tumor Malignancies
NCT00129337
Radiolabeled Monoclonal Antibody in Treating Patients With Glioblastoma Multiforme or Anaplastic Astrocytoma
NCT00004017
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 5 |
| Phase 3 | 1 |
Therapeutic Areas
How the Peregrine Pharmaceuticals early-phase archive is shaped
12 indexed studies, none listed as recruiting (0% open); 11 completed (92%).
Phase mix: 1 late (III/IV) vs 11 early (I/II) (early-phase heavy).
Top condition: Tumors (1 trial), 2 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Peregrine Pharmaceuticals: archived-pipeline peers nationwide
Peers matched on 12 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Peregrine Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 12 archived trials
- Alachua Government Services · 12 trials · 0% recruiting
- Allergy Therapeutics · 12 trials · 0% recruiting
- Ampio Pharmaceuticals. · 12 trials · 0% recruiting
- Angiodynamics · 12 trials · 17% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Peregrine Pharmaceuticals page
12 registered trials is a research-attention snapshot, not an endorsement of Peregrine Pharmaceuticals or any single study.
- None of Peregrine Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Tumors is the condition Peregrine Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Tumors trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Peregrine Pharmaceuticals pipeline card: 12 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.